251 related articles for article (PubMed ID: 34010616)
1. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Won KB; Rha SW; Bae JW; Lee NH; Hur SH; Yoon J; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Han JK; Shin ES; Kim HS;
Lancet; 2021 Jun; 397(10293):2487-2496. PubMed ID: 34010616
[TBL] [Abstract][Full Text] [Related]
2. Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial.
Rhee TM; Bae JW; Park KW; Rha SW; Kang J; Lee H; Yang HM; Kwak SH; Chae IH; Shin WY; Kim DK; Oh JH; Jeong MH; Kim YH; Lee NH; Hur SH; Yoon J; Han JK; Shin ES; Koo BK; Kim HS;
JAMA Cardiol; 2023 Jun; 8(6):535-544. PubMed ID: 37043192
[TBL] [Abstract][Full Text] [Related]
3. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Kang J; Park KW; Lee H; Hwang D; Yang HM; Rha SW; Bae JW; Lee NH; Hur SH; Han JK; Shin ES; Koo BK; Kim HS
Circulation; 2023 Jan; 147(2):108-117. PubMed ID: 36342475
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
[TBL] [Abstract][Full Text] [Related]
5. Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study.
Shin ES; Jun EJ; Kim B; Won KB; Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Han JK; Kim HS;
J Am Heart Assoc; 2023 Apr; 12(8):e026770. PubMed ID: 37042284
[TBL] [Abstract][Full Text] [Related]
6. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
[TBL] [Abstract][Full Text] [Related]
8. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial.
Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS;
Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471
[TBL] [Abstract][Full Text] [Related]
10. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.
Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y;
JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial.
Lee CH; Lee JY; Park GM; Lee SW; Kim HS; Choi YJ; Nam CW; Cho JH; Shin WY; Seo JB; Choi SW; Lee JH; Min PK; Her SH; Lee PH; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
Am J Cardiol; 2018 Feb; 121(4):423-429. PubMed ID: 29273207
[TBL] [Abstract][Full Text] [Related]
12. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
[TBL] [Abstract][Full Text] [Related]
13. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
14. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
Hong SJ; Lee SJ; Suh Y; Yun KH; Kang TS; Shin S; Kwon SW; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee YJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
Circulation; 2024 Feb; 149(8):562-573. PubMed ID: 37878786
[TBL] [Abstract][Full Text] [Related]
15. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
[TBL] [Abstract][Full Text] [Related]
16. Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Lee YJ; Cho JY; Yun KH; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
EuroIntervention; 2022 Aug; 18(6):471-481. PubMed ID: 35470799
[TBL] [Abstract][Full Text] [Related]
17. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
18. Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: A Post Hoc Analysis From the HOST-EXAM Extended Study.
Lee K; Kang J; Park KW; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Yang HM; Kang HJ; Han JK; Shin ES; Koo BK; Kim HS
Can J Cardiol; 2024 Jan; 40(1):43-52. PubMed ID: 37742741
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Yang S; Kang J; Park KW; Hur SH; Lee NH; Hwang D; Yang HM; Ahn HS; Cha KS; Jo SH; Ryu JK; Suh IW; Choi HH; Woo SI; Han JK; Shin ES; Koo BK; Kim HS
J Am Coll Cardiol; 2023 Oct; 82(16):1565-1578. PubMed ID: 37821166
[TBL] [Abstract][Full Text] [Related]
20. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
